We bring you the latest news from the healthcare about the health care in the United Kingdom.

vrijdag 5 oktober 2018

The Lancet: [News] Lurbinectedin for BRCA-mutated advanced breast cancer

[News] Lurbinectedin for BRCA-mutated advanced breast cancer
Patients with BRCA1 or BRCA2-mutated metastatic breast cancer might benefit from treatment with lurbinectedin—a selective inhibitor of active transcription of protein-coding genes—according to a recent study.
Read more

[News] hu3F8 for resistant or recurrent neuroblastoma
A phase 1 trial has found that hu3F8, a humanised anti-GD2 monoclonal antibody, is associated with manageable toxicity, low immunogenicity, and preliminary anti-tumour activity in patients with neuroblastoma.
Read more

[Corrections] Correction to Lancet Oncol 2018; 19: 1289–306
India State-Level Disease Burden Initiative Cancer Collaborators. The burden of cancers and their variations across the states of India: the Global Burden of Disease Study 1990–2016. Lancet Oncol 2018; 19: 1289–306—The appendix of this Article has been updated. The correction has been made to the online version as of Oct 3, 2018.
Read more

[News] Lomustine in older patients with acute myeloid leukaemia
The poor prognosis of older patients with acute myeloid leukaemia (AML) could improve through the addition of lomustine to standard chemotherapy treatment, according to a recent study.
Read more

[News] Brigatinib versus crizotinib for ALK-positive NSCLC
Results of a new study have shown that patients with advanced ALK-positive non-small-cell lung cancer (NSCLC) treated with brigatinib have improved progression-free survival compared with those treated with crizotinib.
Read more